Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy.

Oncotarget · 2016 · PMC4808048 · PMID 26510910

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

The MOSAIC trial documented a nonsignificant trend toward improved survival in patients with high-risk stage II disease who were treated with adjuvant treatment [ 7 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.